ClinicalTrials.gg
RecruitingNCT07287917Updated Oct 22, 2026

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

A Phase 1/2 interventional study of AMXT 1501 Dicaprate and DFMO in Melanoma (Skin Cancer) and HER2-low Hormone Receptor Positive Breast Cancer, sponsored by Aminex Therapeutics, Inc.. Recruiting at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Aminex Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 22, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
92
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,050 studies in Melanoma with a site in United States — 244 open to participants now, 438 under way, 32 of them phase 3. Melanoma · United States.

Planned enrollment
461st of 1,750
92 · median 37
Started
2026
with 51 others
Phase 1/2
287 of 2,050
51 open now
Primary completion
2028-02
later than 290 of 433 live
Registered
1,998th of 2,050
by date

Among the 2,050 studies in Melanoma with a site in United States, this one is the 461st largest by planned enrollment of the 1,750 interventional ones that give a count, is one of 52 that started in 2026, is one of 287 in phase 1/2, reaches primary completion later than 290 of the 433 other live ones, and was the 1,998th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

244 of the 2,050 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

239 more — sign in →

All 244 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,050 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial includes two groups:

  • Cohort 1: Patients with ER+ / HER2- breast cancer receiving fulvestrant and capivasertib
  • Cohort 2: Patients with unresectable or metastatic cutaneous melanoma receiving pembrolizumab

The Phase 1b portion will find the recommended Phase 2 dose (RP2D). The Phase 2 portion will further evaluate clinical activity at the RP2D using response criteria for solid tumors (RECIST 1.1).

The study will also evaluate pharmacokinetics, pharmacodynamics, disease control, and overall safety.

Read the detailed description

This is a multicenter, open-label Phase 1b/2 clinical trial evaluating the combination of oral AMXT 1501 and oral DFMO with standard of care (SOC) therapies in patients with advanced solid tumors who have progressed after prior therapy.

AMXT 1501 is a polyamine transport inhibitor, and DFMO is an inhibitor of polyamine biosynthesis. Together, they are designed to reduce tumor polyamines and potentially improve tumor response to standard cancer treatments. Preclinical and early clinical studies suggest that dual polyamine blockade may reduce tumor growth and reverse tumor-induced immunosuppression.

Cohort 1: ER+ / HER2- Breast Cancer

Patients receive AMXT 1501 + DFMO in combination with:

Fulvestrant 500 mg IM

Capivasertib 400 mg PO BID (4 days on, 3 days off)

Cohort 2: Unresectable or Metastatic Cutaneous Melanoma

Patients receive AMXT 1501 + DFMO in combination with:

Pembrolizumab 200 mg IV every 3 weeks

Phase 1b (Safety Run-In)

The primary objective is to evaluate safety, tolerability, dose-limiting toxicities (DLTs), and to identify the recommended Phase 2 dose (RP2D). A standard 3+3 dose-escalation design is used.

Phase 2 (Dose Expansion)

The study evaluates the efficacy of the combination regimens using:

Objective response rate (ORR)

Duration of response (DOR)

Disease control rate (DCR)

Progression-free survival (PFS)

Overall survival (OS)

Pharmacokinetics, pharmacodynamics, and biomarker analyses (including tumor biopsies) will also be conducted.

Up to approximately 92 patients will be enrolled across the two cohorts.

03

Conditions studied

  • Melanoma (Skin Cancer)
  • HER2-low Hormone Receptor Positive Breast Cancer

Keywords

  • breast cancer
  • melanoma
  • AMXT 1501
  • DFMO
  • polyamine inhibitor
  • advanced solid tumor
  • combination therapy
  • polyamine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients will be eligible for study participation only if they meet ALL the inclusion criteria applicable to their diagnosis.

  1. Understand and sign the form (ICF) and be willing to comply with all study procedures before any study specific procedures are conducted.
  2. ≥18 years old at the time of signing the informed consent.
  3. Diagnosed with unresectable, locally advanced, or solid tumors including ER+ - breast cancer (Cohort 1) or melanoma (Cohort 2)

    a.Underlying malignant disease must be or cytologically documented b.For breast cancer patients: locally advanced or metastatic breast cancer with one or more actionable PIK3CA/AKT1/PTEN-alterations following progression on at least 2 endocrine-based regimens in the metastatic setting or recurrence on or within 12 months of completing therapy. Patients who are candidates to start therapy with capivasertib are eligible for enrollment. Patients previously treated with PIK3CA inhibitors will be allowed into the study. Premenopausal patients with ER+ HER2-breast cancer may be enrolled and should be maintained on an agent for ovarian suppression (i.e., luteinizing hormone-releasing hormone [LHRH] agonist) as part of SOC.

    c.For melanoma patients: patients with unresectable metastatic cutaneous melanoma that progressed on any prior and, if BRAF600 mutant positive, a BRAF or mitogen-activated protein kinase (MEK) inhibitor or both as shown below: i.Patient have to have resolution of all immune checkpoint inhibitor-related adverse events to Grade 0-1 and prednisone ≤10 mg/day for at least 2 weeks. Histologically or cytologically confirmed diagnosis of unresectable Stage III or metastatic melanoma not amenable to local therapy.

    ii.Patients must have progressed or shown intolerance to any prior immune checkpoint inhibitors.

    iii.Patients with BRAF gene mutant melanoma must have had a prior treatment regimen (progressed or shown intolerance) that included vemurafenib, dabrafenib, or an approved BRAF gene and or MEK protein inhibitor. However, patients who may continue to be candidates for immune check point inhibitors can be enrolled prior to initiation for BRAF gene or MEK inhibitors.

    iv.Patients with incurable may be enrolled regardless of the number of prior treatment lines, as long as in the opinion of the Investigator, the patient would be unlikely to tolerate or derive benefit from other available treatment options (FDA Guidance for Industry: Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings. July 2022).

    d.Has evaluable or by tumor Response Evaluable Criteria in Solid Tumors version 1.1 ( 1.1) at the time of enrollment. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

    e.Patients with brain previously treated stable may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of treatment for at least 14 days prior to first dose of study treatment.

  4. Patients must be willing to undergo a fresh tumor at Screening and during treatment if safe and clinically feasible. An archival sample is allowed if obtained within 1 year prior to the first dose of study drug. However, lack of tumor biopsy by itself will not preclude patients from enrollment.
  5. (ECOG) performance status of 0 or 1 at Screening or Day 1.
  6. of at least 12 weeks.
  7. Adequate organ function defined as:

    a. (ANC) ≥1.5×109/L without granulocyte colony-stimulating factor (G-CSF) support within 7 days preceding the laboratory assessment b. ≥100×109/L, without transfusion within 7 days preceding the laboratory assessment c. ≥9 g/dL, without transfusion support within 7 days preceding the laboratory assessment d./partial thromboplastin time (aPTT/PTT) ≤1.5× e. (AST) and alanine aminotransferase (ALT) ≤2.5×ULN (if liver metastases are present, then ≤5×ULN is allowed) f.Total serum ≤1.5×ULN, except for patients with known Gilbert's Syndrome in whom ≤3×ULN is permitted. Confirmation of Gilbert's diagnosis requires elevated unconjugated (indirect) bilirubin values; normal complete blood count in previous 12 months, blood smear, and reticulocyte count; normal aminotransferases and alkaline phosphatase in previous 12 months g.The patient is clinically euthyroid (whether treated or untreated) h.Renal: Serum creatinine ≤1.5×ULN or ≥60 mL/min/1.73 m2 for patients with serum creatinine levels >1.5×ULN i.Any Grade 3 or higher laboratory abnormalities should be discussed and approved by the Sponsor Medical Monitor or designee prior to enrollment (even if not considered clinically significant)

  8. Fully recovered from acute toxic effects of prior anti-neoplastic therapies. The following minimum periods from treatment apply:

    1. Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea).
    2. Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g., Neulasta) or 7 days for short-acting growth factor.
    3. Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.

    The duration of this interval must be discussed with the Sponsor Medical Monitor or designee.

    d.Monoclonal antibodies: >21 days must have elapsed from the infusion of last dose of antibody and toxicity related to antibody therapy must be recovered to Grade ≤1.

    e.Radiation therapy: Patients must have had their last fraction of craniospinal or focal irradiation a minimum of 8-12 weeks prior to enrollment.

    f.Stem cell transplant: Patients must be ≥3 months since stem cell transplant. Patients who received allogenic stem cell transplant or solid organ transplant are not eligible for study.

    g.For combination with pembrolizumab cohort: Patients with Grade ≤2 neuropathy may be eligible, as may patients with endocrine-related Grade ≤2 AEs requiring treatment or hormone replacement.

  9. Active secondary malignancies will not be allowed, with the exception of:

    a.Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer b.Adequately treated Stage 1 cancer from which the patient is currently in remission and has been in remission for ≥2 years c.Low-risk prostate cancer with Gleason score \<7 and prostate-specific antigen \<10 ng/mL d.Any other cancer from which the patient has been disease-free for ≥3 years

  10. Patient compliance and geographic proximity (as determined by the Investigator) to allow adequate follow-up.
  11. Both male and female patients must be willing to consent to using highly effective (refer to Section 9.1.10) prior to study entry, while on treatment, and at least 3 months thereafter.
  12. Able to take oral medications.

Exclusion criteria

Exclusion Criteria:

Patients will not be eligible for study participation if they meet ANY of the exclusion criteria.

  1. Patients with melanoma only:

    i. Radiation therapy, or biological cancer therapy within 4 weeks prior to the first dose of study drug, or not recovered from the AEs due to cancer therapies administered more than 4 weeks earlier ii.Expected to require any other form of systemic or localized antineoplastic therapy while on study.

    iii.Chronic systemic therapy within 2 weeks before the planned date of the first dose of randomized treatment or on any other form of medication.

  2. Intolerant to any component of combination or standard of care therapies.
  3. History or presence of central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis. Patient has known active and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
  4. Active inflammatory neurological disorders (e.g., Guillain-Barre Syndrome, amyotrophic lateral sclerosis, multiple sclerosis).
  5. Treatment with radiation therapy, surgery, chemotherapy, or immunotherapy within 4 weeks prior to study entry (6 weeks for nitrosoureas or Mitomycin C). No prior use of Adriamycin is allowed. Limited prior palliative radiation may be permissible no less than 2 weeks prior to C1D1 with approval from the Sponsor Medical Monitor or designee.
  6. Targeted small molecule therapy within 7 days prior to initiation of trial therapy. Chemotherapy within 14 days prior to initiation of trial therapy.
  7. Active disease (e.g., lupus, rheumatoid arthritis, Sjogren's syndrome) requiring systemic treatment (i.e., disease modifying agents, corticosteroids, or immunosuppressive drugs) in the past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  8. History of or presence of clinically significant cardiovascular disease, e.g.,

    a. Inadequately controlled or uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg on antihypertensive medications.) b. Atherosclerotic cardiovascular disease including history of myocardial infarction, unstable angina, angina, coronary artery disease, cerebrovascular accident (CVA) or (TIA). History of coronary revascularization including coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI) or stent placement is excluded. c. Elevated Troponin I or BNP (or NT-proBNP) blood levels above the at screening or baseline on C1D1.

    d. Heart failure or abnormal (e.g., EF \<50%).

    e. Atrial or ventricular arrhythmias, including atrial fibrillation, ventricular tachycardia. Patients with pacemakers or ICDs (implantable cardioverter defibrillators) are excluded.

    f. Known cardiac involvement of a systemic disease (e.g., as in SLE, rheumatoid arthritis, psoriatic arthritis, systemic sclerosis

  9. History or presence of abnormalities, e.g.,

    a. Congenital or acquired prolonged . Screening QTcF > 450ms is excluded. b. Bundle branch block including right or left bundle branch block, left anterior or posterior fascicular block, second, and 3rd degree AV block, clinically significant ST segment elevations or depressions (e.g., ≥1 mm elevation or ≥0.5 mm depression), arrhythmias. Sinus arrhythmia is not excluded. Asymptomatic sinus bradycardia is not excluded.

  10. Had major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1.
  11. Have active bacterial, viral, or fungal infections requiring systemic therapy.
  12. Women who are pregnant or lactating. NOTE: Women of (WOCBP) must have a "negative" serum pregnancy test within 1 week prior to treatment.

    a.Women not OCBP is defined as: i. with >1 year since last menses and:

1.If \<65 years old, follicle-stimulating hormone (FSH) >40 mIU/mL. 2.If ≥65 years old and not on hormone replacement therapy (HRT), FSH >30 mIU/mL.

3.If ≥65 years old and on HRT, the FSH requirement is not applicable. Postmenopausal females on HRT will be allowed if HRT has been stable for ≥6 months prior to dosing of study drug(s).

4.Written medical documentation of being sterilized (e.g., hysterectomy, double oophorectomy, bilateral salpingectomy) with the procedure performed ≥6 months prior to dosing study drug(s).

Note: Tubal ligation is not considered a form of permanent sterilization. 13.Patients may not have any unresolved toxicity Grade >1 from previous anticancer therapy, except for stable chronic toxicities that are not expected to resolve (i.e., peripheral neuropathy, alopecia, etc.). Patients who have an ongoing requirement for thyroid replacement therapy from prior exposure to an but who are clinically euthyroid are permitted (whether treated or untreated).

14.Have an unwillingness or inability to comply with required procedures in this protocol.

15.Current active liver disease from any cause, including hepatitis A (hepatitis A virus immunoglobulin M [Hep A IgM] positive), (hepatitis B virus [HBV] surface antigen positive), or (hepatitis C virus [HCV] antibody positive, confirmed by HCV ribonucleic acid). Patients with HCV with undetectable virus after treatment are eligible. Patients with a prior history of HBV are eligible if quantitative polymerase chain reaction (PCR) for HBV DNA is negative. Note that elevated levels of biotin may interfere with viral serology testing.

16.Have a serious nonmalignant disease that, in the opinion of the Investigator or the Sponsor Medical Monitor or designee, could compromise protocol objectives.

17.Patients who are currently receiving any other agent or who have received an investigational agent within the last 28 days, with the exception of any patient who participated in Study AMXT1501-101A.

18.Known gastrointestinal (GI) disease or procedure that could interfere with the absorption of study drug, including inability to swallow whole capsules or tablets or conditions that may interfere with absorption. The Sponsor Medical Monitor or designee should be contacted for any questions regarding this exclusion criterion.

19.Patients who have exhibited allergic reactions or intolerability to a similar structural compound, biological agent, or formulation as study drugs used in this study, including AMXT 1501, DFMO, and SOC therapies.

20.Use of other hormonal therapies are not permitted during the study in the breast cancer cohort (Cohort 1). Exception: premenopausal women with ER+/- breast cancer should be maintained on an LHRH agonist for ovarian suppression.

21.Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 μg. Note: Patients who switch from a high dose to a dose of ≤30 μg/day are eligible for study entry.

22.Uncontrolled, acute, or life-threatening bacteria, viral, or fungal infection. Patients with ongoing use of prophylactic antibiotics, antifungals, or antivirals are eligible if no evidence of active infection, this includes COVID patients.

Exception: Patients with well-controlled (e.g., >350/mm3 and undetectable viral load) are eligible.

23.Patient has an active or prior history of autoimmune disease. Exception: patients with type 1 diabetes (if stable, well-controlled, and not brittle), vitiligo, hypo- or hyperthyroid disease, or autoimmune alopecia are permitted if the condition does not require immunosuppressive treatment.

24.Known additional that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, non- squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.

25.Combination with pembrolizumab specific additional exclusion criteria:

  1. Has severe (≥Grade 3) to pembrolizumab and/or any of its .
  2. Has received radiation therapy to the lung that is >30 Gy within 6 months of the first dose of trial treatment.
  3. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  4. Has history of an stem cell transplant or a solid organ transplant.
  5. Has a history of radiation pneumonitis. (Note: Cannot receive prior radiotherapy within 2 weeks of start of pembrolizumab. Note: Participants must have recovered from all radiation-related toxicities and not require corticosteroids. A 1-week is permitted for palliative radiation [≤2 weeks of radiotherapy] to non-CNS disease.
Terms in these criteria, in plain language(42)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    Arm 1: Breast Cancer (ER+ HER2-)

    Arm 1: Breast Cancer Cohort (Cohort 1: ER+ / HER2-) AMXT 1501 oral DFMO oral Fulvestrant IM Capivasertib PO

    Drug: AMXT 1501 Dicaprate · Drug: DFMO · Drug: Fulvestrant · Drug: Capivasertib

  • Experimental
    Arm 2: Melanoma

    Arm 2: Melanoma Cohort (Cohort 2: Melanoma) AMXT 1501 oral DFMO oral Pembrolizumab IV

    Drug: AMXT 1501 Dicaprate · Drug: DFMO · Drug: Pembrolizumab

Interventions

  • DrugAMXT 1501 Dicaprate

    Formulation: Enteric-coated oral tablet (100 mg base) Dose: Body-surface-area-adjusted; starting dose = 300 mg PO BID; may escalate per 3 + 3 design Administration: By mouth on an empty stomach (AM and PM doses)

    Also known as: AMXT 1501

  • DrugDFMO

    Formulation: 500 mg gel capsule Dose: 500 mg PO once or twice daily, per cohort dose level

    Also known as: Difluoromethylornithine

  • Dose: 500 mg IM injection on Day 2 and Day 15 of Cycle 1, then Day 2 of each subsequent 28-day cycle

  • Dose: 400 mg PO BID for 4 days on / 3 days off each week (28-day cycle)

  • 200 mg IV infusion every 3 weeks (Q3W) for up to 12 months

    Also known as: Keytruda®

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicities (DLTs)

    Number of participants experiencing dose-limiting toxicities as defined in the protocol, including hematologic and non-hematologic toxicities, treatment-related dosing delays, missed doses, or any toxicity leading to discontinuation during the DLT evaluation period.

    Time frame: Within 24 months of last patient enrolled

  2. Incidence, Frequency, and Severity of Adverse Events (AEs)

    Assessment of all treatment-emergent adverse events graded using CTCAE v5.0, including clinical labs, vital signs, ECGs, cardiac biomarkers, and physical examinations, to evaluate the safety and tolerability of AMXT 1501 + DFMO with SOC.

    Time frame: Within 24 months of last patient enrolled

  3. Objective Response Rate (ORR) (Phase 2)

    Proportion of participants achieving a confirmed Complete Response (CR) or Partial Response (PR) per RECIST v1.1 as assessed by the investigator.

    Time frame: Within 24 months of last patient enrolled

  4. Duration of Response (DOR) (Phase 2)

    Duration for which a patient maintains a confirmed objective response per RECIST v1.1.

    Time frame: Within 24 months of last patient enrolled

Secondary outcomes

  1. Disease Control Rate (DCR)

    Percentage of participants achieving CR, PR, or Stable Disease (SD) per RECIST v1.1.

    Time frame: Within 24 months of last patient enrolled

  2. Best Overall Response (BOR)

    Best response recorded (CR, PR, SD, or PD) prior to disease progression, based on RECIST v1.1 criteria.

    Time frame: Within 24 months of last patient enrolled

  3. Percentage of Patients With Pseudo-Progression (iRECIST) (Melanoma Cohort)

    Proportion of patients treated with pembrolizumab (melanoma cohort) who demonstrate pseudo-progression based on iRECIST criteria.

    Time frame: Within 24 months of last patient enrolled

  4. Time to Response (TTR)

    Time interval between start of treatment and initial objective tumor response per RECIST v1.1.

    Time frame: Within 24 months of last patient enrolled

  5. Progression-Free Survival (PFS)

    Time from treatment initiation to disease progression per RECIST v1.1 or death from any cause.

    Time frame: Within 24 months of last patient enrolled

  6. Overall Survival (OS)

    Percentage of participants alive at 6 months and 1 year after starting treatment.

    Time frame: Within 36 months of last patient enrolled

  7. Peak Plasma Concentration (Cmax) of AMXT-1501 and DFMO

    Maximum observed plasma concentration (Cmax) of AMXT-1501 and DFMO following oral administration.

    Time frame: During Cycle 1 (each cycle is 28 days)

  8. Trough Plasma Concentration (Cmin) of AMXT-1501 and DFMO

    Predose (trough) plasma concentrations of AMXT-1501 and DFMO at steady state.

    Time frame: Predose during Cycles 2 and later (each cycle is 28 days)

  9. Plasma Concentration-Time Profile of AMXT-1501 and DFMO

    Serial plasma concentrations of AMXT-1501 and DFMO collected to characterize the plasma concentration-time profile.

    Time frame: Serial sampling during Cycle 1 (each cycle is 28 days)

Other outcomes

  1. Change in Immune-Related Gene Expression in Tumor Tissue

    Change from baseline in immune-related gene expression measured by NanoString analysis in tumor tissue.

    Time frame: From baseline (Screening) to end of Cycle 2 (each cycle is 28 days)

  2. Tumor Tissue Concentration of AMXT-1501 and DFMO

    Concentration of AMXT-1501 and DFMO measured in tumor biopsy samples.

    Time frame: At Screening and end of Cycle 2 (each cycle is 28 days)

  3. Tumor Polyamine Levels

    Levels of polyamines measured in tumor tissue samples.

    Time frame: At Screening and end of Cycle 2 (each cycle is 28 days)

  4. eIF5A Hypusination Levels in Tumor Tissue

    Levels of hypusinated eIF5A measured in tumor biopsy samples.

    Time frame: At Screening and end of Cycle 2 (each cycle is 28 days)

07

Study locations

20 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — To be determined.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Feb 2028, 25 months after the start.

Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 84. This study's planned 25 months is below that.

Counting every sponsor, half of 220 studies reached it within 61 months; a quarter within 42 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 17, 2025
StartActual
Jan 26, 2026
Primary completionEst.
Feb 28, 2028
CompletionEst.
Dec 29, 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • University of Rochester Medical Center · Rochester, United States
Show 1 removed
  • START Mountain Region · West Valley City, United States
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    1 site added, 1 site removed
    Show site
    • University of Rochester Medical Center · Rochester, United States
    Show 1 removed
    • START Mountain Region · West Valley City, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07287917
Lead sponsor
Aminex Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Jan 26, 2026
Primary completion
Feb 28, 2028 (estimated)
Completion
Dec 29, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Mark Burns, PhD
Contact
mburns@aminextx.com
425-524-1615
Deyaa Adib, MD
study director · Aminex Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eflornithine

Start the discussion